Other languages Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
54.8 ^USD	+3.63%		+16.87%	+145.96%

11/04	Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI
11/04	Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Praxis Precision Medicines Prices $200 Million Public Offering	28/03
Praxis Precision Medicines Plans Public Equity Offering	28/03
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients	26/03
Praxis Precision Medicines Files $750 Million Mixed-Securities Shelf Registration	05/03
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Praxis Precision Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Praxis Precision Medicines Prices $150 Million Public Offering of Shares, Warrants; Shares Rise	12/01
Sector Update: Health Care Stocks Mixed Premarket Thursday	11/01
Praxis Precision Medicines Plans Public Offering of Common Stock, Warrants; Shares Down Pre-Bell	11/01
Praxis Precision Medicines, Inc. Provides Update on Advancing Clinical Stage Portfolio	08/01
Praxis Precision Signs License Deal With Tenacia for Ulixacaltamide in Greater China	05/01
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China	05/01
Praxis Precision Medicines, Inc. Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies	16/11
Praxis Precision Medicines Says its Elsunersen Receives EMA's PRIME Designation for Potential Epilepsy Treatment	16/11
Praxis Precision Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Praxis Precision Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Praxis Precision Medicines Says Ulixacaltamide Shows Efficacy in Two Additional Analyses of Essential1 Study	08/23/08
Praxis Precision Medicines, Inc. Announces Further Data from Two Additional Analyses of Essential1 Study for Ulixacaltamide	08/23/08
Praxis Precision Medicines Says Brain Mapping Shows PRAX-628 Reaches Brain at Therapeutic Levels	07/23/07
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study	07/23/07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Other languages

Filters